Nipah Virus Low Risk Assessment by WHO Amid Regional Screening

WHO’s Low‑Risk Declaration

In a press briefing in Geneva, Anais Legand, senior official of the WHO Health Emergencies Programme, said the probability that Nipah virus will spread beyond the immediate contacts of the two confirmed Indian patients is “low”. The assessment follows the detection of two laboratory‑confirmed cases in India earlier this month.

The Indian Cases and Immediate Containment

Both patients were admitted to tertiary‑care hospitals, remain alive and one has already shown clinical improvement. Neither travelled while symptomatic, limiting any chance of exportation.

Contact‑tracing teams identified more than 190 individuals—family members, health‑care workers and neighbours—who have been placed under active monitoring. Serial testing of all contacts has been negative and no secondary cases have emerged.

Legand added that WHO is awaiting the viral genome sequence from Indian authorities. “We have not yet seen any genetic changes that would raise concerns about increased transmissibility or virulence,” she said.

Nipah Virus: A Persistent Zoonotic Threat

Nipah is a paramyxovirus first recognised in the 1998–1999 Malaysia outbreak, which claimed more than 100 lives among pig farmers. Fruit bats of the Pteropus genus are the natural reservoir, shedding the virus in saliva, urine and feces.

Human infection can arise from direct bat contact, consumption of contaminated fruit or date‑palm sap, or, less commonly, nosocomial transmission. The disease often begins with fever and can progress rapidly to encephalitis, with a case‑fatality ratio historically ranging from 40 % to 75 %.

There is no specific antiviral therapy; treatment is supportive. Vaccine candidates—most notably a recombinant vesicular stomatitis virus platform—are in pre‑clinical or early Phase I trials, but none are licensed.

Regional Reactions: Screening or Symbolic Gestures?

Following India’s announcement, Hong Kong, Malaysia, Singapore, Thailand and Vietnam have tightened temperature checks and health questionnaires for passengers arriving from the subcontinent. WHO, however, has stated it “does not currently recommend airport screening for Nipah virus.”

Infectious‑disease specialists argue that the virus’s transmission dynamics—requiring close, prolonged contact—make rapid global spread unlikely without a superspreading event.

Professor Piero Olliaro (Oxford University) noted that temperature screenings are of limited utility for a rare pathogen with non‑specific symptoms. “Countries sometimes do these things just to show they are flexing the muscles… telling their people that they’re doing something to protect them,” he said, citing the COVID‑19 experience where fever scanners missed most infected travellers.

What the Scientific Community Wants

Experts agree that limited resources spent on airport screening would be better directed toward three strategic areas:

• Enhanced Surveillance in Endemic Zones – Strengthen community‑based reporting, especially in rural bat‑human interfaces.
• Genomic Characterisation and Data Sharing – Prompt release of viral sequences for real‑time phylogenetic analysis.
• Accelerated Vaccine Development – Coordinate funding, multi‑centre trials and fast‑track regulatory pathways to bring a safe Nipah vaccine to market.

The WHO Emergency Committee will continue to monitor epidemiological data while India’s public‑health messaging emphasizes avoiding raw date‑palm sap, using protective equipment when handling potentially contaminated fruit, and seeking immediate care for unexplained fever or neurological symptoms.

Looking Ahead

The current episode highlights the challenge of balancing visible, reassuring actions with evidence‑based interventions. While airport temperature checks may soothe public fears, they risk creating a false sense of security and diverting attention from more impactful measures such as targeted surveillance, rapid diagnostics and vaccine research.

Given the swift containment of the two Indian cases, the absence of secondary transmission among over a hundred contacts, and no identified viral mutations, WHO’s low‑risk assessment appears justified. Nonetheless, the recurring nature of Nipah spill‑overs in South Asia serves as a reminder that the virus remains a latent threat, poised to re‑emerge when ecological and human behaviours intersect.

Continued vigilance, transparent data sharing, and sustained investment in biomedical research will be essential to prevent future Nipah outbreaks from escalating into a wider health crisis.